You are viewing the site in preview mode
Skip to main content
| |
PTs
|
Saxagliptin
|
Sitagliptin
|
Linagliptin
|
Vildagliptin
|
DPP-4is
|
|---|
|
N
|
ROR(95% CI)
|
N
|
ROR(95% CI)
|
N
|
ROR(95% CI)
|
N
|
ROR(95% CI)
|
N
|
ROR(95% CI)
|
|---|
|
Gastrointestinal
|
Diarrhoea
|
42
|
4.17 (3.04,5.71)*
|
245
|
2.15 (1.88,2.46)*
|
23
|
1.85 (1.22,2.81)*
|
20
|
3.84 (2.44,6.04)*
|
329
|
2.44 (2.16,2.75)*
|
| |
Nausea
|
40
|
3.70 (2.68,5.11)*
|
327
|
2.82 (2.50,3.18)*
|
35
|
2.69 (1.91,3.79)*
|
14
|
2.47 (1.44,4.22)*
|
413
|
3.00 (2.69,3.34)*
|
| |
Vomiting
|
15
|
2.02 (1.21,3.38)*
|
160
|
1.97 (1.67,2.32)*
|
12
|
1.36 (0.77,2.40)
|
14
|
3.77 (2.20,6.46)*
|
200
|
2.04 (1.75,2.37)*
|
| |
Dyspepsia
|
10
|
5.54 (2.94,10.44)*
|
50
|
2.55 (1.89,3.44)*
|
7
|
3.24 (1.53,6.87)*
|
1
|
1.05 (0.15,7.49)
|
68
|
2.95 (2.27,3.85)*
|
|
Pancreas
|
Acute pancreatitis
|
26
|
11.80 (7.89,17.65)*
|
119
|
5.50 (4.46,6.78)*
|
8
|
2.87 (1.42,5.80)*
|
6
|
5.01 (2.22,11.29)*
|
159
|
6.66 (5.50,8.07)*
|
|
Malignancies
|
Pancreatic carcinoma
|
1
|
0.92 (0.13,6.58)
|
122
|
22.04 (16.77,28.97)*
|
4
|
3.18 (1.18,8.57)*
|
1
|
1.81 (0.25,12.97)
|
127
|
19.44 (14.76,25.60)*
|
|
Infection
|
Nasopharyngitis
|
8
|
5.97 (2.94,12.12)*
|
34
|
2.30 (1.61,3.30)*
|
4
|
2.48 (0.92,6.66)
|
1
|
1.42 (0.20,10.12)
|
47
|
2.70 (1.97,3.71)*
|
| |
Pneumonia
|
6
|
1.47 (0.65,3.29)
|
85
|
1.90 (1.52,2.39)*
|
11
|
2.30 (1.26,4.19)*
|
10
|
4.92 (2.62,9.27)*
|
112
|
2.09 (1.71,2.56)*
|
| |
Upper respiratory tract infection
|
6
|
8.52 (3.75,19.36)*
|
71
|
15.71 (11.32,21.80)*
|
1
|
1.15 (0.16,8.25)
|
0
|
–
|
78
|
15.30 (11.01,21.24)*
|
| |
Urinary tract infection
|
5
|
1.79 (0.74,4.33)
|
62
|
2.04 (1.57,2.66)*
|
7
|
2.13 (1.01,4.51)*
|
6
|
4.27 (1.90,9.61)*
|
79
|
2.16 (1.70,2.75)*
|
|
Musculoskeletal
|
Arthralgia
|
13
|
3.46 (1.99,6.02)*
|
145
|
3.87 (3.22,4.64)*
|
10
|
2.23 (1.19,4.18)*
|
7
|
3.63 (1.71,7.71)*
|
173
|
3.88 (3.27,4.60)*
|
| |
Pain in extremity
|
10
|
1.96 (1.05,3.68)*
|
113
|
2.04 (1.67,2.48)*
|
10
|
1.66 (0.89,3.11)
|
6
|
2.31 (1.03,5.20)*
|
138
|
2.05 (1.72,2.46)*
|
| |
Myalgia
|
9
|
3.00 (1.55,5.82)*
|
133
|
4.64 (3.82,5.64)*
|
15
|
4.30 (2.56,7.21)*
|
3
|
1.93 (0.62,6.04)
|
159
|
4.71 (3.93,5.66)*
|
| |
Fracture
|
0
|
–
|
9
|
1.22 (0.62,2.41)
|
0
|
–
|
1
|
3.04 (0.42,21.80)
|
10
|
1.10 (0.58,2.09)
|
|
Cardiac
|
Cardiac failure
|
5
|
1.00 (0.42,2.43)
|
43
|
0.74 (0.54,1.00)
|
9
|
1.54 (0.80,2.99)
|
5
|
1.99 (0.82,4.82)
|
61
|
0.86 (0.66,1.11)
|
| |
Cardiac failure congestive
|
5
|
0.06 (0.02,0.14)
|
53
|
0.05 (0.04,0.06)
|
6
|
0.06 (0.03,0.13)
|
1
|
0.02 (0,0.16)
|
65
|
0.05 (0.04,0.06)
|
| |
Myocardial infarction
|
3
|
0.02 (0.01,0.06)
|
122
|
0.06 (0.05,0.08)
|
14
|
0.08 (0.04,0.13)
|
10
|
0.13 (0.07,0.24)
|
149
|
0.06 (0.05,0.07)
|
|
Hypersensitivity and skin
|
Angioedema
|
20
|
27.80 (17.30,44.65)*
|
50
|
7.06 (5.06,9.86)*
|
5
|
5.21 (2.13,12.72)*
|
0
|
–
|
75
|
10.90 (8.01,14.83)*
|
| |
Oedema peripheral
|
19
|
3.95 (2.49,6.26)*
|
124
|
2.36 (1.95,2.85)*
|
1
|
0.17 (0.02,1.20)
|
13
|
5.32 (3.05,9.30)*
|
156
|
2.47 (2.08,2.94)*
|
| |
Pruritus
|
13
|
3.94 (2.26,6.86)*
|
138
|
4.26 (3.53,5.14)*
|
17
|
4.40 (2.70,7.16)*
|
4
|
2.33 (0.87,6.26)
|
171
|
4.52 (3.79,5.38)*
|
| |
Rash
|
38
|
9.76 (6.99,13.64)*
|
240
|
6.63 (5.70,7.72)*
|
10
|
2.01 (1.07,3.76)*
|
6
|
2.80 (1.24,6.29)*
|
294
|
7.17 (6.21,8.28)*
|
| |
Rash generalised
|
3
|
4.43 (1.41,13.96)*
|
42
|
7.27 (5.04,10.47)*
|
7
|
9.08 (4.23,19.49)*
|
0
|
–
|
52
|
8.09 (5.71,11.44)*
|
| |
Urticaria
|
21
|
12.47 (7.97,19.51)*
|
74
|
4.20 (3.25,5.43)*
|
10
|
4.78 (2.54,6.90)*
|
0
|
–
|
104
|
5.31 (4.22,6.67)*
|
| |
Pemphigoid
|
3
|
8.37 (2.63,26.64)*
|
9
|
2.25 (1.12,4.53)*
|
20
|
63.72 (37.92,107.09)*
|
16
|
112.37 (63.87,197.70)*
|
47
|
23.33 (14.44,37.68)*
|
|
General disorders
|
Asthenia
|
8
|
1.36 (0.67,2.73)
|
111
|
1.71 (1.40,2.08)*
|
26
|
3.87 (2.61,5.75)*
|
4
|
1.33 (0.49,3.56)
|
148
|
1.89 (1.59,2.25)*
|
| |
Dizziness
|
15
|
1.75 (1.05,2.93)*
|
224
|
2.48 (2.15,2.86)*
|
25
|
2.51 (1.68,3.75)*
|
5
|
1.13 (0.47,2.74)
|
269
|
2.46 (2.16,2.81)*
|
| |
Fatigue
|
14
|
1.92 (1.13,3.27)*
|
141
|
1.74 (1.46,2.08)*
|
15
|
1.74 (1.04,2.91)*
|
5
|
1.33 (0.55,3.22)
|
175
|
1.78 (1.52,2.09)*
|
| |
Headache
|
19
|
2.87 (1.81,4.54)*
|
286
|
4.51 (3.95,5.15)*
|
22
|
2.82 (1.84,4.32)*
|
2
|
0.57 (0.14,2.30)
|
329
|
4.33 (3.82,4.91)*
|
| |
Malaise
|
14
|
2.26 (1.33,3.86)*
|
130
|
1.91 (1.59,2.29)*
|
13
|
1.77 (1.02,3.07)*
|
23
|
7.73 (5.04,11.84)*
|
180
|
2.22 (1.90,2.61)*
|
| |
Pain
|
18
|
2.18 (1.36,3.49)*
|
122
|
1.29 (1.07,1.55)*
|
13
|
1.32 (0.76,2.28)
|
1
|
0.23 (0.03,1.64)
|
154
|
1.33 (1.13,1.57)*
|
- FAERS FDA Adverse Event Reporting System
- Dpp-4is Dipeptidyl peptidase-4 inhibitors
- N The number of adverse events reports
- ROR The reporting odds ratio
- CI The confidence interval
- PTs Preferred Terms
- *: signal detected, see “Methods” for the criteria of detection
